Trans-arterial chemoembolization (TACE) in patients with unresectable hepatocellular carcinoma: Experience from a Tertiary Care Centre in India

Indian Journal of Radiology and Imaging

Volumn 21, Issue 2, 2011, Pages 113-120

  Paul, Shashi Bala ^a   Gamanagatti, Shivanand ^a   Sreenivas, Vishnubhatla ^a   Chandrashekhara, Sheragaru Hanumanthappa ^a   Mukund, Amar ^a   Gulati, Manpreet Singh ^a   Gupta, Arun Kumar ^a   Acharya, Subrat Kumar ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Hepatocellular carcinoma; Survival rate; Transarterial chemoembolisation

Indexed keywords

ACETIC ACID; ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER MORTALITY; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CHEMICAL ANALYSIS; CHEMOEMBOLIZATION; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; FEVER; FOLLOW UP; HEPATOGRAPHY; HUMAN; INDIA; INOPERABLE CANCER; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER SIZE; LIVER WEIGHT; MAJOR CLINICAL STUDY; MALE; NAUSEA; OVERALL SURVIVAL; PORTAL HYPERTENSION; PREDICTION; SURVIVAL RATE; SURVIVAL TIME; TERTIARY HEALTH CARE; TREATMENT RESPONSE; TUMOR VOLUME; VOMITING;

EID: 79960207687     PISSN: 09713026     EISSN: 19983808     Source Type: Journal    
DOI: 10.4103/0971-3026.82294     Document Type: Article

References (32)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden. Globocan 2000. Int J Cancer 2001;94:153-6. (Pubitemid 32911406)
2. Tanaka H, Hiyama T, Tsukuma H, Okubo Y, Yamano H, Kitada A, et al. Prevalence of second generation antibody to hepatits C antibody among voluntary blood donors in Osaka, Japan. Cancer Causes Control 1994;5:409-13. (Pubitemid 24302704)
3. Kumar A, Srivastava DN, Chau TT, Long HD, Bal C, Chandra P, et al. Inoperable hepatocellular carcinoma: Transarterial 188Re HDD-labeled iodized oil for treatment-prospective multicenter clinical trial. Radiology 2007;243:509-19. (Pubitemid 46649708)
4. Yumoto Y, Jinno K, Tokuyama K, Araki Y, Ishimitsu T, Maeda H, et al. Hepatocellular carcinoma detected by iodized oil. Radiology 1985;154:19-24. (Pubitemid 15196277)
5. Konno T, Maeda H, Iwai K, Tashiro S, Maki S, Morinaga T, et al. Effect of arterial administration of high-moleculan-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma. Eur J Cancer Clin Oncol 1983;19:1053-65. (Pubitemid 13045311)
6. Ohishi H, Uchida H, Yoshimura H, Ohue S, Ueda J, Katsuragi M, et al. Hepatocellular carcinoma detected by iodized oil: Use of anticancer agents. Radiology 1985;154:25-9. (Pubitemid 15196278)
7. Takayasu K, Shima Y, Muramatsu Y, Moriyama N, Yamada T, Makuuchi M, et al. Hepatocellular carcinoma: Treatment with intraarterial iodized oil with and without chemotherapeutic agents. Radiology 1987;163:345-51. (Pubitemid 17068905)
8. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 2002;359:1734-9. (Pubitemid 34607087)
9. Caturelli E, Siena DA, Fusilli S, Villani MR, Schiavone G, Nardella M, et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: Evaluation of damage to nontumorous liver tissue-long-term prospective study. Radiology 2000;215:123-8. (Pubitemid 30190520)
10. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006;131:461-9. (Pubitemid 44142456)
11. Ji SK, Cho YK, Ahn YS, Kim MY, Park YO, Kim JK, et al. Multivariate analysis of the predictors of survival for patients with hepatocellular carcinoma undergoing transarterial chemoembolization: Focusing on superselective chemoembolization. Korean J Radiol 2008;9: 534-40.
12. Savastano S, Miotto D, Casarrubea G, Teso S, Chiesura-Corona M, Feltrin GP. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with Child's grade A or B cirrhosis: A multivariate analysis of prognostic factors. J Clin Gastroenterol 1999;28:334-40. (Pubitemid 29246409)
13. Miyayama S, Yamashiro M, Okuda M, Yoshie Y, Sugimori N, Igarashi S, et al. Chemoembolisation for the treatment of large Hepatocellular carcinoma. J Vasc Interv Radiol 2010;21:1226-34.
14. Pisani P, Parkin DM, Ferlay J. Estimates of the world wide mortality from eighteen major cancers in 1985. Implications for prevention and projections of future burden. Int J Cancer 1993;55:891-3.
15. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108. (Pubitemid 40372904)
16. Paul SB, Chalamalasetty SB, Vishnubhatla S, Madan K, Gamanagatti SR, Batra Y, et al. Clinical Profile, Etiology and Therapeutic Outcome in 324 Hepatocellular Carcinoma Patients at a Tertiary Care Center in India. Oncology 2009;77:162-71.
17. Acharya SK, Madan K, Dattagupta S, Panda SK. Viral hepatitis in India. Natl Med J India 2006;19:203-17. (Pubitemid 44596410)
18. Kumar R, Saraswat MK, Sharma BC, Sakhuja P, Sarin SK. Characteristics of hepatocellular carcinoma in India: A retrospective analysis of 191 cases. Q J Med 2008;101:479-85. (Pubitemid 351791532)
19. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of esophagus for bleeding esophageal varices. Br J Surg 1973;60:646-8.
20. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK, et al. EASL Panel of Experts on HCC. EASL panel of experts on HCC: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona EASL conference. European Association for the study of liver. J Hepatol 2001;35:421-30 (Pubitemid 32844200)
21. Cillo U, Vitale A, Grigoletto F, Farinati F, Brolese A, Zanus G, et al. Prospective validation of the Barcelona Clinic Liver Cancer staging system. J Hepatol 2006;44:723-31.
22. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:1907-17. (Pubitemid 37518510)
23. Sarin SK, Thakur V, Guptan RC, Saigal S, Malhotra V, Thyagarajan SP, et al. Profile of hepatocellular carcinoma in India: An insight into the possible etiologic associations. J Gastroenterol Hepatol 2001;16:666-73. (Pubitemid 34188842)
24. Murugavel KG, Mohan KV, Pramod NP, Rajasambandam P, Mathews S, Jyanthi V, et al. Correlation of hepatitis B and C viral markers with aflatoxin and AFP in Hepatocellular carcinoma cases from Tamil Nadu. Abstract. Indian J Gastroenterol 1999;18:S37.
25. Kapoor S, Gupta SK, Sehgal RK, Dhiman RK, Chawla Y, Jyotsana. Hepatocellular carcinoma at PGI Chandigarh. Indian J Gastroenterol 1999;18:S36-24.
26. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. N Engl J Med 1995;332:1256-61.
27. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-71. (Pubitemid 34454013)
28. Vetter D, Wenger JJ, Bergier JM, Doffoel M, Bockel R. Transcatheter oily chemoembolization in the management of advanced hepatocellular carcinoma in cirrhosis: Results of a Western comparative study in 60 patients. Hepatology 1991;13:427-33.
29. Ernst O, Sergent G, Mizurahi D, Delemazure O, Paris J-C, L'Hermine C. Treatment of hepatocellular carcinoma by transcatheter arterial chemoembolization: Comparison of planned periodic chemoembolization and chemoembolization based on tumor response. Am J Roentgenol 1999;172:59-64. (Pubitemid 29028431)
30. Jansen MC, van Hillegersberg R, Chamuleau RA, van Delden OM, Gouma DJ, van Gulik TM. Outcome of regional and local ablative therapies for hepatocellular carcinoma: A collective review. Eur J Surg Oncol 2005;31:331-47. (Pubitemid 40521297)
31. Pelletier G, Ducreux M, Gay F, Luboinski M, Hagège H, Dao T, et al. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: A multicenter randomized trial. Groupe CHC. J Hepatol 1998;29:129-34. (Pubitemid 28307992)
32. Pelletier G, Roche A, Ink O, Anciaux ML, Derhy S, Rougier P, et al. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990;11:181-4.